Researchers at the University of Washington have found that an existing FDA-approved drug could enhance the effectiveness of immunotherapy against fibrolamellar carcinoma, a rare type of liver cancer that has historically been unresponsive to checkpoint inhibitors. The discovery offers new hope for patients with this challenging disease and may extend to other cancer types, according to the study published recently.
Fibrolamellar carcinoma primarily affects adolescents and young adults, and standard treatments like surgery and chemotherapy have limited success. Immunotherapy, specifically checkpoint inhibitors, has revolutionized cancer treatment for many cancers, but fibrolamellar carcinoma has shown resistance. The University of Washington team identified that the FDA-approved drug, when used in combination with checkpoint inhibitors, boosted the immune system's ability to attack tumors in preclinical models.
While this study focused on fibrolamellar carcinoma, other cancer types are also receiving unprecedented research attention from companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which is developing novel immunotherapies. The potential to repurpose an already approved drug could accelerate treatment options and reduce costs, as safety profiles are already established.
The findings underscore the importance of continued research into mechanisms of immunotherapy resistance. The University of Washington team plans to move toward clinical trials to test the combination in patients with fibrolamellar carcinoma. If successful, this approach could be applied to other cancers that do not respond to checkpoint inhibitors alone.
BioMedWire, a specialized communications platform focusing on biotechnology and life sciences, notes that such breakthroughs are critical for advancing cancer care. The platform, part of the Dynamic Brand Portfolio @IBN, provides access to a vast network of wire solutions, article syndication to 5,000+ outlets, and tailored corporate communications. For more information, visit BioMedWire.
This discovery highlights the potential for drug repurposing in oncology, offering a faster path to effective treatments for rare cancers. It also emphasizes the need for ongoing investment in biomedical research to unlock new therapeutic combinations.
